Guernsey will offer weight loss injections to up to 300 people during a two-year trial that could lead to the treatment being made available on prescription, the government has announced.
Dr. George Oswald, President of Health and Social Care, emphasized the potential benefits of the medication. “If you look at bangs for your bucks, there’s no doubt at all [that the medication delivers results] much more quickly and much more effectively than traditional methods,” he said.
Currently approved for patients with type 2 diabetes, the injections work by mimicking a natural hormone that regulates appetite. The Public Health-led trial will evaluate how the medication impacts overall health, with the aim of determining its broader potential use.
“Where there’s a place for them, we need to use them,” Deputy Oswald added, noting that he hoped the trial’s results would support an extended rollout through the Policy and Resources Committee.
Oswald highlighted the wide-ranging health benefits of weight management, explaining that obesity, particularly morbid obesity, affects numerous aspects of health—from colon cancer and osteoarthritis to conditions affecting neurodevelopment, including dementia. “By controlling that, we hope to make a major impact,” he said.
While the treatment shows promise in improving quality of life and potentially reducing healthcare costs, Dr. Oswald stressed it should complement, not replace, preventive measures such as healthy eating and regular exercise.
